- QIAGEN expands next-generation sequencing portfolio with QIAseq Normalizer kits
- Normalizes various library types over a broad range of concentrations in only 30 minutes
- QIAseq kits have processed more than four million NGS samples
Venlo, the Netherlands, July 5, 2023 – QIAGEN today announced the launch of the QIAseq Normalizer Kits that give researchers a fast, convenient and cost-effective method to pool different DNA libraries for best-quality results from next-generation sequencing (NGS) runs.
The QIAseq Normalizer Kit speeds up equalizing DNA concentrations across NGS libraries – so-called normalization – to 30 minutes from several hours by ending the need for quantifying DNA libraries using time-intensive and expensive procedures. It is high-throughput with an optimized protocol for parallel normalization of 96 samples, automation-friendly, and works without hazardous chemicals.
“The QIAseq Normalizer’s big strength is its ability to reliably normalize all library types across a wide range of concentrations quickly and cheaply,” said Dr. Thomas Schweins, Senior Vice President and Head of QIAGEN’s Life Sciences Business Area. “Library pooling is the key to cost-effective, high-yield multiplexed sequencing – and QIAGEN’s normalization kit is crucial for ensuring researchers get consistent and high-quality sequencing data by minimizing any uneven representation of libraries.”
Researchers can use QIAseq Normalizer with QIAGEN’s existing QIAseq library prep solutions to streamline NGS workflows – or with a range of DNA- and RNA-library prep workflows from other providers for Illumina sequencing platforms. QIAseq Normalizer results in double-stranded DNA libraries, which are compatible with long-term storage and much more stable than the single-stranded libraries that competing products yield.
The new kit adds to QIAGEN's growing next-generation sequencing portfolio that harnesses the true potential of NGS in biological research by offering fast and efficient solutions that reduce turnaround times and maximize sequencing capacity. With a focus on front-end sample processing and downstream bioinformatics, QIAGEN provides innovative NGS technologies for genomics, transcriptomics, epigenomics, and metagenomics applications.
QIAGEN’s QIAseq kits have processed over four million NGS samples, enabling biomarker research, gene expression studies, viral epidemiology, and disease surveillance. From DNA and RNA sequencing to multimodal sequencing and epigenomics, the comprehensive range of QIAseq kits delivers reliable data on any sequencing instruments.
The bioinformatics portfolio of QIAGEN Digital Insight complements its sample processing technology to leverage the full potential of NGS on any sequencing platform. To maintain a leading position in the industry, QIAGEN actively nurtures strategic partnerships to advance next-generation sequencing companion diagnostics. These tests provide valuable information that can help guide clinical decision-making and improve patient outcomes by identifying patients most likely to benefit from a particular therapeutic product.
Learn more about QIAGEN’s QIAseq Normalizer kits for NGS at https://www.qiagen.com/applications/next-generation-sequencing/normalization.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.